Tag:
Medarex
Latest Headlines
Latest Headlines
Bristol CEO touts successful biopharma blitz after big hep C play
Bristol-Myers Squibb ( $BMY ) mounted an enviable makeover from a diversified company to a biopharma force over the past several years, with the famed "String of Pearls" strategy advanced to buy
Trial results, M&A lead biotech to hot July
A lot of attention has been paid to the biotech industry's struggles this year. A derth of funding options have caused many biotechs to cut jobs, suspend programs or go out of business entirely. But
Bristol inks $2.4B deal for Medarex
Bristol-Myers Squibb agreed to buy Medarex for about $2.4 billion to double its pipeline of experimental biological drugs, including one nearing U.S. approval for skin cancer. Report
Bristol-Myers to buy Medarex for $2.1B
Anxious to beef up its pipeline, Bristol-Myers Squibb announced late Wednesday that it had struck a deal to buy Medarex for $2.4 billion. But the dealmakers note that the $300 million on Medarex's
Medarex shares rise on surprising cancer study
Shares of Medarex shot up 17 percent after investigators at the Mayo Clinic say they were startled by the level of success seen in a trial of a monoclonal antibody for prostate cancer. Two of the men
Medarex shares boosted by mid-stage RA data
Shares of Medarex were buoyed this morning on the news that its experimental rheumatoid arthritis drug met its primary endpoint in a mid-stage trial. And the results are paving the way to a new round
Medarex snares $225M deal for C. diff program
Medarex and Massachusetts Biologic Laboratory will share an upfront payment of $60 million and up to $165 million in milestones from Merck, which is licensing an antibody they discovered for C.
Medarex shares dented on analysts' skepticism
Investors dented the value of Medarex shares after analysts doused its recent claims concerning its late-stage cancer drug ipilimumab with cold water. BMO Capital Market's Jason Zhang says that
Medarex shares slide on news of drug app delay
Shares of Medarex slipped seven percent this morning as investors digested Friday's announcement that its application for a new cancer drug will be delayed into 2009. The developer says that the FDA
Pfizer halts Phase III cancer trial on poor results
Pfizer's big push into cancer drugs has hit a snag. The company announced that it is halting a late-stage trial of tremelimumab for advanced melanoma after researchers concluded it was no more
